Page 137 - 《中国药房》2022年9期
P. 137

表面积,可实现核酸类药物的高效负载;其次,研究人员                               complexes using prefunctionalized polymers for synchro-
        可筛选性能不同的纳米材料,合成不同形状、大小、化学                               nous delivery of doxorubicin and siRNA to cancer
        组成、多孔结构的纳米颗粒,并对其进行表面修饰,可使                               cells[J]. Biomaterials,2013,34(20):4849-4859.
        纳米载体针对不同的荷载药物,表现出不同的药代动力                           [ 8 ]  KUMAR Y,KUCHE K,SWAMI R,et al. Exploring the
        学性质和药效动力学性质。利用不同纳米材料构建的                                 potential of novel pH sensitive lipoplexes for tumor targe-
        刺激响应型核酸类药物递送载体已经克服了非病毒载                                 ted gene delivery with reduced toxicity[J]. Int J Pharm,
                                                                2020,573:118889.
        体核酸递送过程中的大部分障碍,但相较于临床应用的
                                                           [ 9 ]  SCHAFER F Q,BUETTNER G R. Redox environment of
        实际需求,许多非病毒核酸类药物递送载体在转染效
                                                                the cell as viewed through the redox state of the gluta-
        率、生物安全性等方面仍有巨大的提升空间,载体的潜
                                                                thione disulfide/glutathione couple[J]. Free Radic Biol
        在毒性和全身清除效率的研究还有待进一步展开。
                                                                Med,2001,30(11):1191-1212.
            研究者若想要构建高效、低毒且精准靶向的智能响
                                                           [10]  CHENG R,FENG F,MENG F H,et al. Glutathione-
        应型核酸类药物纳米载体,需要考虑到核酸药物的化学
                                                                responsive nano-vehicles as a promising platform for
        修饰、纳米材料的功能化、载体的制备技术以及给药途                                targeted intracellular drug and gene delivery[J]. J Control
        径的选择,同时需要结合具有可预测药代动力学和药效                                Release,2011,152(1):2-12.
        学特性的联合策略,以及明确的作用机制等。在许多情                           [11]  MOLLAZADEH S,MACKIEWICZ M,YAZDIMAMAGHANI
        况下研究人员在构建载体时不可能对这些条件进行直                                 M. Recent advances in the redox-responsive drug delivery
        接的排列组合比较,这些策略的正确性均会决定纳米载                                nanoplatforms:a chemical structure and physical property
        体是否能够构建成功。另外,目前蓬勃发展的人工智能                                perspective[J]. Mater Sci Eng C Mater Biol Appl,2021,
        和计算机建模的应用为解决这些问题也提供了一个新                                 118:111536.
        方向。                                                [12]  SON S,SINGHA K,KIM W J. Bioreducible BPEI-SS-
        参考文献                                                    PEG-cNGR polymer as a tumor targeted nonviral gene
        [ 1 ]  YIN H,KANASTY R L,ELTOUKHY A A,et al. Non-viral  carrier[J]. Biomaterials,2010,31(24):6344-6354.
             vectors for gene-based therapy[J]. Nat Rev Genet,2014,  [13]  MUTLU AGARDAN N B,SARISOZEN C,TORCHILIN
             15(8):541-555.                                     V P. Redox-triggered intracellular siRNA delivery[J].
        [ 2 ]  CHEN J,LIN L,GUO Z P,et al. Synergistic treatment of  Chem Commun(Camb),2018,54(49):6368-6371.
             cancer stem cells by combinations of antioncogenes and  [14]  SONG S J,LEE S,LEE Y,et al. Enzyme-responsive de-
             doxorubicin[J].J Drug Deliv Sci Technol,2015,30:417-  stabilization of stabilized plasmid-lipid nanoparticles as
             423.                                               an efficient gene delivery[J]. Eur J Pharm Sci,2016,91:
        [ 3 ]  FENTONO S,OLAFSONK N,PILLAIP S,et al. Advances   20-30.
             in biomaterials for drug delivery[J/OL]. Adv Mater,2018  [15]  TAKEMOTO H,MIYATA K,NISHIYAMA N,et al. Bio-
             [2022-03-01]. https://pubmed.ncbi.nlm.nih.gov/29736981/.  responsive polymer-based nucleic acid carriers[J]. Adv
             DOI:10.1002/adma.201705328.                        Genet,2014,88:289-323.
        [ 4 ]  LI Y M,YANG J H,XU B,et al. Enhanced therapeutic  [16]  LI X,SUN A N,LIU Y J,et al. Amphiphilic dendrimer en-
             siRNA to tumor cells by a pH-sensitive agmatine-chitosan  gineered nanocarrier systems for co-delivery of siRNA
             bioconjugate[J]. ACS Appl Mater Interfaces,2015,7(15):  and paclitaxel to matrix metalloproteinase-rich tumors for
             8114-8124.                                         synergistic therapy[J/OL]. NPG Asia Mater,2018[2022-
        [ 5 ]  LIBERTI M V,LOCASALE J W. The Warburg effect:    03-01]. http://www.nature.com/articles/s41427-018-0027-4.
             how does it benefit cancer cells? [J]. Trends Biochem Sci,  DOI:10.1038/s41427-018-0027-4.
             2016,41(3):211-218.                           [17]  ZHANG W M,ZHANG J,QIAO Z,et al. Functionally
        [ 6 ]  WORSLEY C M,VEALE R B,MAYNEE S. The acidic       oriented tumor microenvironment responsive polymeric
             tumour microenvironment:manipulating the immune re-  nanoassembly:engineering and applications[J]. Chin J
             sponse to elicit escape[J/OL]. Hum Immunol,2022[2022-  Polym Sci,2018,36(3):273-287.
             03-01].https://pubmed.ncbi.nlm.nih.gov/35216847/. DOI:  [18]  KIM J,LEE Y M,KIM H,et al. Phenylboronic acid-sugar
             10.1016/j.humimm.2022.01.014.                      grafted polymer architecture as a dual stimuli-responsive
        [ 7 ]  DONG D W,XIANG B,GAO W,et al. pH-responsive      gene carrier for targeted anti-angiogenic tumor therapy[J].


        中国药房    2022年第33卷第9期                                              China Pharmacy 2022 Vol. 33 No. 9  ·1151 ·
   132   133   134   135   136   137   138   139   140